WHO Issues First-Ever Guidance to Speed Up Better Tuberculosis Tests Worldwide

GENEVA — The World Health Organization (WHO) has published its first-ever guidance on how researchers, developers and funders should build evidence for new tuberculosis (TB) diagnostic tests, a move the agency says will help better tests reach the people who need them faster. Released on October 20, 2026, the guidance is the third document in WHO's evidence-generation series, following earlier guidance on new TB treatment regimens and TB preventive treatment, according to WHO.

Illustration: A concept illustration of a modern laboratory working on tuberculosis diagnostic tests.

What Happened

The WHO guidance, formally titled Guidance on Evidence Generation for new tuberculosis diagnostics, sets out how evidence should be produced so that it can best inform WHO guideline development on new diagnostic tests, sample types and testing strategies. It is aimed at researchers, test developers, funders and other stakeholders whose work shapes future WHO recommendations, according to the agency's announcement.

The document covers the full arc of diagnostic research: study design, participant selection, sample-size calculations and reporting standards. Crucially, it goes beyond the question of whether a test is accurate in a laboratory. It also calls for evidence on outcomes that matter to patients and health systems, including cost-effectiveness, equity, acceptability and feasibility, according to WHO and reporting by Devdiscourse.

"Robust evidence is the foundation of strong WHO recommendations," said Tereza Kasaeva, Director of WHO's Department for HIV, Tuberculosis, Hepatitis and Sexually Transmitted Infections. "This guidance gives researchers, developers and funders a clear road map for generating the evidence WHO needs on innovative tuberculosis tests, sample types and testing strategies, so that better diagnostics reach more people who need them, faster."

One of the guidance's central innovations is a new analytical framework that maps the role of a diagnostic test across the clinical pathway — from the first suspicion of disease through testing, diagnosis and treatment decisions — and links each stage to appropriate study designs, populations, methods and reporting requirements. The idea, WHO says, is that researchers designing a study should start from the test's intended role in care, not from accuracy alone.

Commentary on the guidance published on October 23, 2026, noted that it sets out 28 key messages, beginning with the need for teams to define a test's value proposition and prepare an analytical framework before choosing a study design. That framework asks teams to align participant selection with the target population, evaluate the test in its intended setting of use, include a relevant standard-of-care comparator, justify the reference standard and collect a sample large enough for precise estimates.

Background

Tuberculosis remains one of the world's deadliest infectious diseases, despite being preventable and curable. According to WHO's Global Tuberculosis Report 2025, an estimated 10.7 million people fell ill with TB in 2024 — 5.8 million men, 3.7 million women and 1.2 million children — and the disease claimed an estimated 1.23 million lives that year, including 150,000 people living with HIV. TB remains the world's leading cause of death from a single infectious agent, according to WHO.

Diagnosis is where the fight against TB is often won or lost. Millions of people with TB are never diagnosed at all: WHO estimates that around 2.4 million people with TB went undiagnosed in 2024, and about 390,000 cases of multidrug-resistant or rifampicin-resistant TB were recorded. A test that works well in a reference laboratory may perform very differently in a rural clinic with limited electricity, trained staff or sample transport — which is why WHO's guidance insists that evidence must cover real-world feasibility, not just accuracy.

The new guidance also arrives alongside other recent WHO work to close evidence gaps in TB care. On October 13, 2026, the agency launched a research toolkit aimed at the safe inclusion of pregnant and breastfeeding women in TB drug and vaccine trials, a group historically excluded from clinical research despite an estimated 336,900 pregnant and postpartum women contracting TB each year, according to WHO's TB Research Knowledge Portal.

Funding remains a persistent constraint. WHO has reported that funding for TB prevention, diagnosis and treatment has been essentially flat since 2020, reaching US$5.9 billion in 2024 — just over a quarter of the US$22 billion annual target. Modelling studies cited in recent reporting warn that lasting cuts to international donor funding could lead to up to 2 million additional deaths and 10 million more people falling ill between 2025 and 2035.

General information disclaimer: This article provides general information about a public health announcement and is not medical advice. It makes no claims about diagnosis, treatment or cure for any individual. Anyone concerned about tuberculosis symptoms or testing should consult a qualified health professional or local health service.

Illustration: A concept illustration of tuberculosis screening in a community clinic.

Why It Matters

The guidance matters because the path from a promising diagnostic prototype to a WHO recommendation — and from a recommendation to a clinic shelf — has often been slow and uneven. Previous studies, WHO says, sometimes had methodological weaknesses, excluded vulnerable populations, concentrated on test accuracy while providing too little information on feasibility, acceptability, equity and costs, or reported results inconsistently, making findings difficult to compare and synthesize.

By setting a common standard for evidence generation, WHO hopes to reduce wasted research effort and speed up the adoption of tests that genuinely improve care. A developer that follows the road map from the outset should produce evidence that guideline panels can actually use, rather than evidence that has to be re-done or set aside. For patients, the practical payoff could be faster, more accurate diagnosis closer to home — and fewer people falling through the cracks between testing and treatment.

The guidance also matters for equity. By explicitly requiring evidence on equity, acceptability and feasibility, it pushes developers to consider from the start whether a test will work for children, for people living with HIV, for pregnant women and for communities far from major hospitals — not just for the easiest-to-reach patients. That emphasis aligns with WHO's broader push to close the gap between the people who develop TB and the people who get diagnosed and treated.

There is also a global health security dimension. Drug-resistant TB is one of the most serious antimicrobial resistance threats, and faster, more reliable detection of resistance is essential to getting patients onto effective treatment quickly and to preventing further transmission. Tests that can detect drug resistance at the point of care, backed by solid evidence, are among the most valuable tools in that effort.

Illustration: A concept illustration of researchers studying global tuberculosis data.

What Happens Next

Researchers and developers working on new TB diagnostics are now expected to use the guidance when designing and reporting their studies, and funders can use it as a benchmark when deciding which studies to support. WHO says the guidance, together with its existing target product profiles for TB diagnosis and drug-resistance detection, provides a framework connecting diagnostic innovation with evidence-based policy.

The next test of the guidance will be practical: whether upcoming diagnostic studies are designed differently, report more completely, and move more quickly through guideline review. WHO's guideline panels will be watching for studies that demonstrate not only accuracy but also patient-important outcomes, cost-effectiveness and feasibility in the settings where TB burden is highest.

For the broader TB response, the guidance is one piece of a larger puzzle that still includes closing the funding gap, expanding access to existing tests and treatments, and tackling the risk factors that drive the epidemic — undernutrition, HIV infection, diabetes, smoking and alcohol use disorders, according to WHO. Progress on deaths and cases has resumed since the COVID-19 pandemic disrupted services, but WHO has warned repeatedly that those gains remain fragile without sustained political commitment and investment.

Sponsored: explore today's featured sponsored offers

FAQ

What exactly has WHO published?

WHO has published its first Guidance on Evidence Generation for new tuberculosis diagnostics, released on October 20, 2026. It tells researchers, developers and funders how to design and report studies of new TB tests, sample types and testing strategies so the results can inform WHO recommendations.

Why does WHO say accuracy alone is not enough?

A test can be accurate in a laboratory but impractical in a real clinic. WHO's guidance therefore also requires evidence on cost-effectiveness, equity, acceptability and feasibility, as well as on outcomes that matter to patients, such as whether testing leads to faster treatment.

How big is the tuberculosis problem today?

According to WHO's Global Tuberculosis Report 2025, an estimated 10.7 million people fell ill with TB in 2024 and 1.23 million died, including 150,000 people living with HIV. Around 2.4 million people with TB went undiagnosed that year.

What is the new analytical framework in the guidance?

It is a tool that maps a diagnostic test's role across the clinical pathway and links each stage to suitable study designs, populations, methods and reporting. It helps researchers design studies around how a test will actually be used in care.

Will this guidance change testing for patients soon?

Not overnight. The guidance shapes future research and guideline decisions, so its effects will appear as new studies are designed to its standard and as better-evidenced tests move through WHO review and into national programs.

Sources

• World Health Organization — "WHO launches guidance on evidence generation for new TB diagnostics" — October 21, 2026
• Devdiscourse — "WHO Guidance Sets Evidence Standards for the Next Generation of TB Diagnostic Tests" — October 22, 2026
• Voice of Healthcare — "WHO Issues Guidance on New TB Diagnostics" — October 2026
• World Health Organization — Global Tuberculosis Report 2025 (data for 2024)
• Agence France-Presse (via media reports) — "Tuberculosis killed 1.23 million last year: WHO" — November 2025